4 ms·
Imminotherapies very quickly kill a significant percentage of the people who try them. So it’s a complicated balancing act when someone is likely to die in say
by Retric 3y ago
Imminotherapies very quickly kill a significant percentage of the people who try them. So it’s a complicated balancing act when someone is likely to die in say 1-2 years but also likely to survive another 6 months.
For people who are likely to die very soon the case is more clear cut, but the people developing these treatments don’t have the resources or infrastructure to try and treat more than a tiny handful of people. Allowing people to pay for such treatments also opens the door for a huge range of bad actors which also costs lives. I am not saying the current system is great, just that there’s a lot more complexity than is obvious on the surface.
- eilertokyo 3y agoYour comment makes something that happens quite rarely (1-5% based on agent, and not quickly) seem like it happens quite frequently.
- Retric 3y agoSome of these trials had double digit percentage deaths within 30 days.
- adamredwoods 3y agoBecause the trials sometimes take on people with very little time left.
- Retric 3y agoThat’s the estimate for number of people killed by the treatment not the number of people who died in total. You should be careful not to exclude trials cancelled early when considering how risky trials are.
- eilertokyo 3y agoPlease provide some examples if you can! I could use the references